Mathilde Cancel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7737285/publications.pdf

Version: 2024-02-01

2258059 2053705 6 140 3 5 citations h-index g-index papers 6 6 6 184 docs citations citing authors times ranked all docs

#	Article	IF	CITATIONS
1	CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) Journal of Clinical Oncology, 2022, 40, 492-492.	1.6	13
2	Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	1.9	0
3	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: AÂpooled analysis of historical data. European Journal of Cancer, 2022, 170, 158-168.	2.8	2
4	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. European Journal of Cancer, 2021, 150, 108-118.	2.8	16
5	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). European Journal of Cancer, 2021, 158, 1-11.	2.8	4
6	Efficacy of Savolitinib vs Sunitinib in Patients With <i>MET </i> li>-Driven Papillary Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1247.	7.1	105